Literature DB >> 15534256

Late-onset Pompe disease primarily affects quality of life in physical health domains.

M L C Hagemans1, A C J W Janssens, L P F Winkel, K A Sieradzan, A J J Reuser, P A Van Doorn, A T Van der Ploeg.   

Abstract

OBJECTIVE: To investigate quality of life in an international population of patients with late-onset Pompe disease.
METHODS: Data on quality of life (SF-36), age, sex, disease duration, wheelchair use, and use of artificial ventilation were collected for 210 adults with Pompe disease from Australia, Germany, the Netherlands, the United Kingdom, and the United States. SF-36 scores were compared between countries and related to patient characteristics. In addition, for the Dutch subgroup (n = 51), comparisons with the general population and 1-year follow-up assessments were performed.
RESULTS: No significant differences between countries were found for the four physical health scales. Mean scores on the vitality, role functioning-emotional, and mental health scale differed between countries, but these differences were not consistent. Wheelchair use was associated with lower physical and social functioning scores (B = -23.6 and -15.1, p < 0.001), and the use of artificial ventilation with lower physical functioning scores (B = -8.4, p = 0.004). Patients reported significantly poorer quality of life than the general population on the physical functioning, role functioning-physical, general health, vitality, and social functioning scales. No significant differences in SF-36 scores were found between the baseline and 1-year follow-up measurement.
CONCLUSIONS: Patients with late-onset Pompe disease are, on average, markedly affected on the physical health domains of quality of life, but score only slightly lower than the general population on the mental health domains.

Entities:  

Mesh:

Year:  2004        PMID: 15534256     DOI: 10.1212/01.wnl.0000142597.69707.78

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

Review 1.  Quality of life in rare genetic conditions: a systematic review of the literature.

Authors:  Julie S Cohen; Barbara B Biesecker
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

2.  Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.

Authors:  Stefania Zampieri; Emanuele Buratti; Silvia Dominissini; Anna Lisa Montalvo; Maria Gabriela Pittis; Bruno Bembi; Andrea Dardis
Journal:  Eur J Hum Genet       Date:  2010-12-22       Impact factor: 4.246

3.  Therapeutic advances in the management of Pompe disease and other metabolic myopathies.

Authors:  Corrado Angelini; Anna Chiara Nascimbeni; Claudio Semplicini
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

Review 4.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

5.  Qualitative and quantitative skeletal muscle ultrasound in late-onset acid maltase deficiency.

Authors:  Craig M Zaidman; Elizabeth C Malkus; Catherine Siener; Julaine Florence; Alan Pestronk; Muhammad Al-Lozi
Journal:  Muscle Nerve       Date:  2011-07-13       Impact factor: 3.217

6.  Autophagy in Natural History and After ERT in Glycogenosis Type II.

Authors:  Corrado Angelini; Anna C Nascimbeni; Marina Fanin
Journal:  JIMD Rep       Date:  2015-02-25

7.  Inspiratory Muscle Training in Late-Onset Pompe Disease: The Effects on Pulmonary Function Tests, Quality of Life, and Sleep Quality.

Authors:  Goksen Kuran Aslan; Burcu Ersoz Huseyinsinoglu; Piraye Oflazer; Nilgun Gurses; Esen Kiyan
Journal:  Lung       Date:  2016-04-22       Impact factor: 2.584

8.  Fatigue: an important feature of late-onset Pompe disease.

Authors:  Marloes L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

9.  Fatigue is part of the burden of neuromuscular diseases.

Authors:  John H J Wokke
Journal:  J Neurol       Date:  2007-02-26       Impact factor: 4.849

Review 10.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.